Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Duchenne Muscular Dystrophy Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

64 recruiting trials for Duchenne Muscular Dystrophy. Eligibility criteria explained in plain English.

TrialFinderData lists 64 Duchenne Muscular Dystrophy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 24% (6 studies); the largest phase groups are Phase 1 / Phase 2: 6, Phase 2: 4, Early Phase 1: 4, Phase 3: 4.

Research is led by Seoul National University Hospital (3), Italfarmaco (3), Centre Hospitalier Universitaire de Liege (2), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (drug, 6 trials), followed by wearable technology, SGT-003.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
64
Total Trials
64
Recruiting Now
4
Phase 3 Trials
10
Sponsors

Track Duchenne Muscular Dystrophy trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06539169

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in...

Sponsor: xCuresEnrolling: 10001 location
RECRUITINGNCT05982119

Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study

The objective of the ActiLiège Next study is to collect longitudinal data from patients and control subjects using a wearable magneto-inertial device. By collecting natural...

Sponsor: Centre Hospitalier Universitaire de LiegeEnrolling: 3008 locations
RECRUITINGNCT06093100

Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim

Duchenne Muscular Dystrophy (DMD) is an X-linked disorder that causes muscle wasting, cardiopulmonary failure, and premature death. Heart failure is a leading cause of death in...

Sponsor: Vanderbilt University Medical CenterEnrolling: 101 location
RECRUITINGNCT06925269

DMD Voice: Qualitative Interviews With Patients and Caregivers

The purpose of this study is to understand DMD functional losses or abilities and their association with independence and quality of life from the perspective of individuals with...

Sponsor: Red Nucleus Enterprise Solutions, LLCEnrolling: 681 location
RECRUITINGNCT06773988

Follow-up of NIV At Home in Patients with Duchenne Muscular Dystrophy

The aim of this study is to verify whether full video home polysomnography (sleep study) with nocturnal transcutaneous CO2 monitoring is feasible in the follow-up of non-invasive...

Sponsor: Universitaire Ziekenhuizen KU LeuvenEnrolling: 171 location
RECRUITINGNCT01484678

Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy

The purpose of this research study is to determine the potential of magnetic resonance imaging, spectroscopy, and whole body imaging to monitor disease progression and to serve as...

Sponsor: University of FloridaEnrolling: 5503 locations
RECRUITINGNCT06755138

Research on the Relationship Between Scoliosis, Pain, Quality of Life, and Trunk Muscle Compensation Patterns Among...

* Objective: The objective of this observational study is to evaluate and quantify trunk muscle compensatory movement patterns in patients with Duchenne Muscular Dystrophy (DMD)...

Sponsor: Seoul National University HospitalEnrolling: 301 location
RECRUITINGNCT07378553

Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies

The purpose of this research study is to determine the potential of a multiparametric ultrasound approach to non-invasively monitor disease progression and to serve as an...

Sponsor: Nantes University HospitalEnrolling: 601 location
RECRUITINGPhase 1 / Phase 2NCT06138639

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

This is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with...

Sponsor: Solid Biosciences Inc.Enrolling: 6015 locations
RECRUITINGNCT07415837

Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies

The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases. MicroRNAs (miRs)...

Sponsor: University Hospital, Clermont-FerrandEnrolling: 1041 location
RECRUITINGNCT07286565

Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal...

The Active NBS Liege study is a monocentric, academic, fully remote, observational study designed to validate digital measures of motor development in children with spinal...

Sponsor: Centre Hospitalier Universitaire de LiegeEnrolling: 1001 location
RECRUITINGNCT07332013

Urinary Titin Biomarker in DMD

A universal challenge in clinical investigation of novel therapeutics is the need for quantitative, objective biomarkers that directly address the mechanisms of disease and...

Sponsor: Children's Hospital of PhiladelphiaEnrolling: 501 location
RECRUITINGNCT07609394

Duchenne Electronic Health Record Study

This study aims to collect retrospective and prospective, long-term data of patients with dystrophinopathy (including Duchenne, Becker, and female carriers) through electronic...

Sponsor: The Duchenne RegistryEnrolling: 250010 locations
RECRUITINGPhase 1 / Phase 2NCT07037862

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and...

This is a study of the investigational medicine ENTR-601-44 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition. The researchers want to: Test...

Sponsor: Entrada Therapeutics, Inc.Enrolling: 2414 locations
RECRUITINGNCT06564974

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

The goal of this study is to collect additional information on the safety of long-term treatment with AGAMREE® and to explore long-term clinical impact of AGAMREE® on quality of...

Sponsor: Catalyst Pharmaceuticals, Inc.Enrolling: 25020 locations
RECRUITINGPhase 2NCT06290713

Vasodilator and Exercise Study for DMD (VASO-REx)

Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve...

Sponsor: University of FloridaEnrolling: 501 location
RECRUITINGEarly Phase 1NCT06485661

Effect of Captopril on GLS in Duchenne Myodystrophy

To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with...

Sponsor: Ain Shams UniversityEnrolling: 201 location
RECRUITINGNCT07515235

DMD Gene Variants and Cardiac Dysfunction in Young Males With Dystrophinopathies

The goal of this observational study is to investigate whether the type, location, and extent of pathogenic variants in the DMD gene are associated with cardiac dysfunction in...

Sponsor: Aristotle University Of ThessalonikiEnrolling: 651 location
RECRUITINGPhase 4NCT05412394

Once Weekly Infant Corticosteroid Trial for DMD

The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.

Sponsor: Anne M. ConnollyEnrolling: 264 locations
RECRUITINGNCT04972604

CureDuchenne Link®: A Resource for Research

CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and self- and/or caregiver-reported information from participants. Anyone over 4 weeks old who...

Sponsor: CureDuchenneEnrolling: 500010 locations
RECRUITINGNCT06147414

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 5501 location
RECRUITINGPhase 1 / Phase 2NCT07429240

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

The purpose of this Phase 1/2a trial is to evaluate the safety, tolerability, and preliminary efficacy of PBGENE-DMD in patients with DMD harboring mutations amenable to excision...

Sponsor: Precision BioSciences, Inc.Enrolling: 182 locations
RECRUITINGNCT06366815

phenotypeS in Non Ambulant Duchenne Muscular Dystrophy

The aims of the study are to prospectively collect information on several aspects of function in non-ambulant DMD patients by using a structured battery of tests including motor,...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 2502 locations
RECRUITINGNCT04012671

A Registered Cohort Study on Duchenne Muscular Dystrophy

Dystrophinopathy is a term of X-linked recessive genetic disease, including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and the X-linked dilated cardiomyopathy. The...

Sponsor: Ning Wang, MD., PhD.Enrolling: 20001 location
RECRUITINGPhase 3NCT07608432

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in...

The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory...

Sponsor: Dyne TherapeuticsEnrolling: 901 location
RECRUITINGNCT07015632

ML-Based Multi-Sensor Fall Risk Screening in DMD

This prospective observational study aims to analyze changes in upper extremity functional movement over time in children with Duchenne Muscular Dystrophy (DMD). Thirty patients...

Sponsor: Seoul National University HospitalEnrolling: 301 location
RECRUITINGPhase 1 / Phase 2NCT07058662

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular...

The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-D101 to treat participants with Duchenne Muscular Dystrophy.

Sponsor: Belief BioMed (Beijing) Co., LtdEnrolling: 91 location
RECRUITINGEarly Phase 1NCT06641895

Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy

The purpose of the study is to assess the safety, tolerability, and efficacy of BBM-D101 to treat patients with Duchenne Muscular Dystrophy.

Sponsor: Shanghai Jiao Tong University School of MedicineEnrolling: 61 location
RECRUITINGNCT06363357

The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients...

The goal of this clinical trial is to investigate the effect of a muscle-mimicking, fabric-type shoulder orthosis on functional movements of the upper limb in patients with...

Sponsor: Seoul National University HospitalEnrolling: 301 location
RECRUITINGNCT07436143

Effects of Posture and Quality of Life in Duchenne Muscular Dystrophy Children

Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder predominantly affecting boys and men, with an estimated incidence of 1 in 3,800 to 1 in 6,200...

Sponsor: Riphah International UniversityEnrolling: 331 location
RECRUITINGNCT06402942

Gamified Occupational Therapy for Adolescents With Duchenne Muscular Dystrophy

This research aims to improve the quality of life, occupational performance, occupational satisfaction and emotional health of young people with Duchenne muscular dystrophy...

Sponsor: Başak Çağla ArslanEnrolling: 201 location
RECRUITINGNCT06574919

Clinical and Functional Assessment of Patients With Inherited Non-Duchenne Myopathies in Sohag University Hospital

Muscular Myopathies are a heterogenous group of inherited muscular disorders characterized by progressive muscle weakness. Historically, these disorders are difficult to treat. In...

Sponsor: Sohag UniversityEnrolling: 303 locations
RECRUITINGPhase 1NCT06692426

Trial of Cell Based Therapy for DMD

This is a single-center, single-arm, interventional phase 1 trial to evaluate the safety and tolerability of local injection of induced pluripotent stem cell (iPSC)- derived CD54+...

Sponsor: Masonic Cancer Center, University of MinnesotaEnrolling: 81 location
RECRUITINGNCT05016908

Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy

Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators...

Sponsor: Massachusetts General HospitalEnrolling: 1002 locations
RECRUITINGPhase 3NCT07160634

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male...

Sponsor: Solid Biosciences Inc.Enrolling: 805 locations
RECRUITINGPhase 1NCT06224660

Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

This research study is testing whether an experimental drug, called SRD-001, is safe and helps the weakened heart of patients with Duchenne muscular dystrophy (DMD) regain its...

Sponsor: Sardocor Corp.Enrolling: 123 locations
RECRUITINGPhase 3NCT05933057

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

This is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant male paediatric (aged 9...

Sponsor: ItalfarmacoEnrolling: 13820 locations
RECRUITINGPhase 3NCT05066633

The Efficacy and Safety of Metoprolol as add-on Treatment to Standard of Care in Preventing Cardiomyopathy in Patients...

The study includes 150 patients with DMD diagnosis confirmed by genetic testing, 8-16 years old (≥8 and \<17) at the study entry with a follow-up of up to 5 years. Random...

Sponsor: Medical University of GdanskEnrolling: 1501 location
RECRUITINGNCT06833489

Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases

Since 2017, more than 250 analyses performed at the Molecular Genetics Laboratory of the Timone Enfant Hospital have yielded negative results in patients with rare genetic muscle...

Sponsor: Assistance Publique Hopitaux De MarseilleEnrolling: 501 location
RECRUITINGPhase 1 / Phase 2NCT04906460

Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

This is a Phase 1b/2 open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in...

Sponsor: Wave Life Sciences USA, Inc.Enrolling: 265 locations
RECRUITINGNCT07467187

Invasive Home Ventilation in Denmark

The aim of this study is to describe national trends over the past 10 years in patients receiving invasive home mechanical ventilation (HMV) in Denmark. This includes indications...

Sponsor: Rigshospitalet, DenmarkEnrolling: 4501 location
RECRUITINGNCT07039799

The Effect of Virtual Reality Applications on Upper Extremity Functions in Patients With Duchenne Muscular Dystrophy

This study aims to evaluate the effects of fully immersive virtual reality (VR) applications on upper extremity (UE) functions in individuals diagnosed with Duchenne Muscular...

Sponsor: Istanbul UniversityEnrolling: 361 location
RECRUITINGEarly Phase 1NCT07188012

Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients

The primary objective of this study is to evaluate the safety and tolerability of SPOT-03 administered by intravenous (IV) infusion to DMD patients. In addition, this study will...

Sponsor: Shanghai Siponuoyin Biotechnology Co LtdEnrolling: 91 location
RECRUITINGPhase 2 / Phase 3NCT05693142

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal...

Sponsor: REGENXBIO Inc.Enrolling: 6517 locations
RECRUITINGPhase 2NCT05996003

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations...

Sponsor: NS Pharma, Inc.Enrolling: 2020 locations
RECRUITINGNCT00390104

Molecular Analysis of Patients With Neuromuscular Disease

The purpose of this study is to identify new genes responsible for neuromuscular disorders and study muscle tissue of patient with known neuromuscular disease, as well as their...

Sponsor: Boston Children's HospitalEnrolling: 10001 location
RECRUITINGNCT05019625

Biomarker Development for Muscular Dystrophies

Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators...

Sponsor: Massachusetts General HospitalEnrolling: 4655 locations
RECRUITINGNCT07423026

A Remote Study Using Technology to Assess Outcomes in DMD

Every year, 100 boys are born in the UK with a rare muscle disease called Duchenne muscular dystrophy. These boys cannot make an important muscle protein called dystrophin. They...

Sponsor: University of OxfordEnrolling: 601 location
RECRUITINGNCT07129954

Fear of Falling in Muscular Dystrophy

Primary objectives WP1: Evaluate the prevalence of FOF in the study population and how this varies over time. Evaluate whether there are relationships between the variables...

Sponsor: Universita di VeronaEnrolling: 1001 location
RECRUITINGPhase 1NCT04626674

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in...

Cohort 8 (non-ambulatory participants) is currently enrolling new participants. Enrollment for Cohorts 1 through 7 has been completed. This is an open-label gene transfer therapy...

Sponsor: Sarepta Therapeutics, Inc.Enrolling: 837 locations

Showing 50 of 64 trials.Search all Duchenne Muscular Dystrophy trials

Frequently Asked Questions

There are currently 64 clinical trials for Duchenne Muscular Dystrophy, with 64 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Duchenne Muscular Dystrophy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 4 Phase 3 trials for Duchenne Muscular Dystrophy, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.